Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
S-1 + cisplatin
- Development stage
- Unknown
- Lead developer
- Taiho Pharmaceutical
- Modality
- Peptides, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
S-1 + cisplatin is a combination chemotherapy regimen primarily used for the treatment of advanced gastric and gastroesophageal adenocarcinoma. S-1 is an oral fluoropyrimidine derivative designed to improve the efficacy and tolerability of 5-fluorouracil (5-FU) by combining tegafur (a prodrug of 5-FU) with two modulators that enhance its activity and reduce gastrointestinal toxicity. Cisplatin is a platinum-based alkylating agent that exerts its antineoplastic effects by forming DNA cross-links, thereby inhibiting DNA replication and transcription which leads to cell death. The combination has demonstrated noninferior overall survival compared to infusional 5-FU/cisplatin regimens with a better safety profile in phase 3 clinical trials for advanced gastric cancer[2][3][5][7].
- Brand names
- TS-1TS1TS 1S-1S1S 1
- Other names
- S-1 + cisplatin
02
Targets
DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on S-1 + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on S-1 + cisplatin.